by | Jul 3, 2024 | Publications
Ann Hematol. 2024 Jul 3. doi: 10.1007/s00277-024-05806-9. Online ahead of print. ABSTRACT We aimed to evaluate if circulating plasma cells (CPC) detected by flow cytometry could add prognostic value of R2-ISS staging. We collected the electronic medical records of 336...
by | Jul 3, 2024 | Publications
Sci Rep. 2024 Jul 2;14(1):15142. doi: 10.1038/s41598-024-65937-x. ABSTRACT Multiple myeloma (MM) is an incurable hematological malignancy with poor survival. Accumulating evidence reveals that lactylation modification plays a vital role in tumorigenesis. However,...
by | Jul 3, 2024 | Publications
Leukemia. 2024 Jul 2. doi: 10.1038/s41375-024-02306-7. Online ahead of print. NO ABSTRACT PMID:38956316 | DOI:10.1038/s41375-024-02306-7
by | Jul 3, 2024 | Publications
Oncologist. 2024 Jul 2:oyae111. doi: 10.1093/oncolo/oyae111. Online ahead of print. ABSTRACT BACKGROUND: Multiple myeloma (MM) is the second most common hematological malignancy with its prevalence increasing. Patients with symptomatic MM can show numerous...
by | Jul 2, 2024 | Publications
Am J Hematol. 2024 Jul 2. doi: 10.1002/ajh.27425. Online ahead of print. ABSTRACT Central nervous system (CNS) involvement is a rare and aggressive complication of multiple myeloma (MM). We identified 54/4352 MM patients (1.2%), who developed CNS-MM between 2000 and...
by | Jul 2, 2024 | Publications
Mol Carcinog. 2024 Jul 2. doi: 10.1002/mc.23787. Online ahead of print. ABSTRACT Somatic mutations and polymorphisms may play a role in multiple myeloma (MM) susceptibility and survival. One of the immune checkpoint inhibitors is P-selectin glycoprotein ligand-1...
